Trials: Gynecologic Cancer

Disease Sites Included: Cervical, Ovarian, Uterus/Endometrial, Vaginal, Vulvar

You are here:

Find a Clinical Trial
Gynecologic Cancer

Assessing Dynamic Changes in the Plasma Proteome to Identify Clinically Relevant Early Detection and Treatment Response Biomarkers for High Grade Serous Ovarian Cancer: A CPTAC Pilot Project.

June 10, 2026

NCT04251052 – A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician’s Choice in Participants With Endometrial Cancer Who Have Received Prior Platinum-based Chemotherapy and Anti-PD-1/PD-L1 Immunotherapy

June 10, 2026

NCT05256225 – NRG-GY026: a Phase ii/iii Study of Paclitaxel/Carboplatin Alone or Combined With Either Trastuzumab and Hyaluronidase-Oysk (Herceptin Hylecta) or Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf (Phesgo) in Her2 positive, Stage i-iv Endometrial Serous Carcinoma or Carcinosarcoma

June 10, 2026

NCT05548296 – A Phase 1b/2 Basket Study of ACR-368 as Monotherapy and in Combination with Gemcitabine in Adult Subjects with Platinum-Resistant Ovarian Carcinoma, Endometrial Adenocarcinoma, and Urothelial Carcinoma Based on Acrivon OncoSignature® Status

June 10, 2026

NCT06072781 – A Phase 3, Randomized, Open-Label Study of Combination Therapy with Avutometinib plus Defactinib Versus Investigator’s Choice of Treatment in Patients with Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)

June 10, 2026

NCT06157151 – A Randomized, Open Label, Two-Arm, Multicenter Phase 2 Study to Evaluate Efficacy and Safety of PRGN-2009 in Combination with Pembrolizumab Versus Pembrolizumab Monotherapy in Patients with Recurrent or Metastatic Cervical Cancer

June 10, 2026

NCT06515613 – A Phase 1, First-in-Human Study of CTIM-76, a Claudin-6 (CLDN6)-Directed Bispecific Antibody, in Patients with Recurring Ovarian Cancer and Other Advanced Solid Tumors

June 10, 2026

NCT06580314 – NRG GY036 A Phase III Trial of One vs. Two Years of Maintenance Olaparib, with or Without Bevacizumab, in Patients with BRCA1/2 Mutated or Homologous Recombination Deficient (HRD+) Ovarian Cancer Following Response to First Line Platinum-Based Chemotherapy

June 10, 2026

NCT06586957 – A Randomized, Open Label, Two-Arm, Multicenter Phase 2 Study to Evaluate Efficacy and Safety of PRGN-2009 in Combination with Pembrolizumab Versus Pembrolizumab Monotherapy in Patients with Recurrent or Metastatic Cervical Cancer

June 10, 2026

Validation of OvaPrintTM cell-free DNA Methylation Liquid Biopsy in women with Pelvic Masses

June 29, 2026